iododoxorubicin
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 1999 (NCT00003853)
Timeline
Indications
Mechanism of action
- Topoisomerase I/IIINHIBITOR
Topoisomerase I/II inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 4'-deoxy-4'-idx
- 4'-deoxy-4'-iododoxorubicin
- 4'-iodo-4'-deoxydoxorubicin
- 4'-iodo-4'-deoxydoxorubicin
- 4'-iodo-4'-deoxydoxorubicin
- 4'-iododeoxyrubicin
- 4'-iododoxorubicin
- fce 21954
- fce-21954
- iododoxorubicin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00030381 | Phase 1 | Dec 1, 2001 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00003853 | Phase 2 | Apr 1, 1999 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 2 | 0 | 2 | 1999 |
| National Cancer Institute (NCI) | Government | 2 | 2 | 2 | 1999 |
2 organizations
Page 1 / 1